tbuckley/cabot-search huggingface dataset:
AB1035 Anxiety in Caregivers of Patients with Chronic Rheumatic Conditions
Authors: A.K.M. Gutierrez-Rubio, G. Racaza, M.L. Dianongco, E. Penserga
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Caregivers of patients with chronic illnesses may experience depression and anxiety. The psychological and emotional impact to caregivers of patients with rheumatologic conditions, especially those caring for patients with disability, may lead to increased morbidity and mortality. <h3>Objectives</h3> Our primary objective was to determine the prevalence of anxiety in caregivers of patients with SLE, RA, and OA, seen at the Philippine General Hospital. <h3>Methods</h3> Demographic data was collected. The HADS-P, a 14-item rating scale with independent subscales for anxiety and depression, was administered to each patient. A score of 11 or higher indicated probable depression or anxiety. <h3>Results</h3> A total of 438 patients were included in this study. All patients included were acting as the caregiver of an individual with a rheumatologic condition, with 182, 151, and 107 caring for patients with SLE, RA, and OA, respectively. The prevalence of probable depression among caregivers of patients with SLE, RA, and OA were 2.2±10%, 0±0%, and 1.9±10%, respectively with a 95% CI. The prevalence of probable anxiety among caregivers of patients with SLE (17.58±10%) was significantly higher than, RA and OA (9.93±10% <i>p =0.05</i>, and 8.57±10% <i>p =0.</i>04, respectively). Other variables, such as low income, presence of comorbid illnesses, or the number of hours per day spent caring for the patient were not found to be significant factors. <h3>Conclusions</h3> The prevalence of anxiety among caregivers of patients with SLE were found to be significantly higher than those of other rheumatologic conditions, implying that the illness of the patient they are caring for impacts their risk for anxiety. More studies are needed to determine risk factors for anxiety among caregivers of patients with SLE, and the impact this may have on patient care. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4037
Abstract 4170: Primary Orthotopic Hepatocellular Carcinoma Models for Evaluation of Anticancer Drugs
Authors: Dawei Chen, Taiping Chen, Jean-Pierre Wery, Yiyou Chen
Journal: Cancer Research (2010)

Abstract Human primary tumor model represents better alternatives for preclinical drug evaluation than cell lined derived xenograft models, due to its preservation of tumor tissue organization and pathology. At the same time, orthotopic xenograft models have also been used to better mimic the human patho-physiologic conditions such as vascularization, tumor expansion, and local microenvironmental factors. Here we combined the orthotopic transplantation method with our primary HCC models. The initial tumor inoculate was derived from a HCC patient tumor which was maintained subcutaneously in nude mice with limited passages. Tumor fragment was then anchored to the anterior hepatic lobe of nude mice. The Plasma AFP level of the orthotopic tumor bearing mice were determined once per week in order to correlate with the tumor volume. We have applied several standard care anticancer drugs to evaluate this model. Cisplatin (5mg/kg, q3d x 4) and Sorafinib (50mg/kg, qd x14), were dosed for 2 weeks after randomized grouping based upon the serum AFP levels of tumor bearing mice. The procedure of HCC fragments inoculation for this orthotopic model was successful and efficient. The tumor take rate of transplantation is over 90%. AFP level in tumor bearding mice plasma could be used as a biomarker to monitor tumor burden. These results indicated that primary orthotopic HCC model is a powerful tool for the evaluation of the drugs targeting heptocellular carcinoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4170.
Cytembena: Condensation of the Carcinogenesis Bioassay Technical Report
Authors: James Huff
Journal: Environmental Health Perspectives (1982)

because preliminary clinical results from Czechoslovakia indicated that this chemical might have use as a cytostatic agent (1-4).Clinical trials in the United States were discontinued because no apparent antineoplastic effects were seen (5-7). MethodsMale and female inbred Fischer 344 rats and male and female hybrid B6C3F1 mice, obtained from Frederick Cancer Research Center, were used in this study.Control and treated groups comprised 50 animals of each species and sex.For 104 consec- utive weeks all groups were fed Wayne Lab Blox.Three times per week treated groups were given intraperitoneal injections of 7 or 14 mg/kg (for rats) and 12 or 24 mg/kg (for mice) of cytembena (99.4% pure).Control groups received 0.9% saline injections.This carcinogenesis bioassay was conducted dur- ing January
1177 BASELINE Phospho-Stat1 LEVEL IN PBMC IS A NON-INVASIVE BIOMARKER OF EARLY VIROLOGICAL RESPONSE TO TRIPLE THERAPY IN CHRONIC HCV INFECTION – ANRS C10–08 STUDY
Authors: P. Sultanik, A. Casrouge, C. Br'echot-Alanio, E. Mottez, L. Bousquet, D. Amroun, S. Feton, K. Sperber, S. Pol, M.L. Albert, V. Mallet
Journal: Journal of Hepatology (2013)
SP0031 How To Select The Most Appropriate Capillaroscopic Device: Pros and Cons
Authors: W. Hermann
Journal: Annals of the Rheumatic Diseases (2016)

One of the most important indications for performing capillaroscopy is to differentiate between primary and secondary Raynaud9s syndrome. Different kinds of microscopes are at hand and generally vary in terms of picture quality or price. Before purchasing a microscope and capillaroscopy software, several considerations about the required standards of examination should be made; some of which are summarized as follows: –The region of interest (ROI). Normal capillaries have a mean diameter of about 8 μm. For an accurate assessment a magnification of 100–200x is recommended, for an overview the magnification of 50x is sufficient. –Measurement. Beside qualitative measures like changes in vessel architecture, there should be the possibility of quantifying the number of capillaries/mm or vessel diameters. –Documentation. All parts of the examination have to be stored and assigned to patient and case. –Practical aspects and handling of the device. –Different kinds of microscopes are on the market of which three will be discussed in detail. Briefly summarized: –Stereo microscopes. Advantages: Very good image quality, zooming in and out without problems, relatively easy to use. Disadvantages: device is not mobile, in patients with finger contractures examinations are difficult to perform, relatively high costs. – Videocapillaroscopes: Advantages: Very good image quality, easy to use, “gold standard” for capillaroscopy. Disadvantages: No overview, zooming in and out not applicable (change of lenses required), relatively high costs. – USB microscopes: Advantages: low costs, zooming in and out without problems, easy to use. Disadvantages: limited picture quality, documentation laborious. Selecting a capillaroscopic device depends on the conditions of use (“quick look” vs. “academic evaluation and follow up”), which should be clarified before buying a device. The price range is significant and usually differs between 100€ for USB microscopes and up to 10,000€ for stereo and videocapillaroscopes. <h3>Literatur</h3> <h3>References</h3> Cutolo M et al. How to perform and interpret capillaroscopy. Best Pract Res Clin Rheumatol. 2013;27(2):237–48. Cutolo M et al. State of the art on nailfold capillaroscopy: a reliable diagnostic tool and putative biomarker in rheumatology? Rheumatology (Oxford). 2013;52(11):1933–40. Hermann W, Meier FMP, Müller-Ladner U. Is less than 100 Euro sufficient for a capillary microscope? Z Rheumatol 2013;72(6):520–522. <h3>Disclosure of Interest</h3> None declared
ANXIETY IS MORE COMMON THAN DEPRESSION IN ADULTS WITH CONGENITAL HEART DISEASE
Authors: Lisa Deng, Abigail May Khan, David Drajpuch, Stephanie Fuller, Lacey P. Gleason, Jonathan Ludmir, Christopher E. Mascio, Sara L. Partington, Lynda Tobin, Yuli Y. Kim, Adrienne Kovacs
Journal: Journal of the American College of Cardiology (2015)
Abstract 3923: ATM and KAP1 are required for nonhomologous end-joining in transcriptionally active chromatin
Authors: Amy J. Hawkins, David E. White, Sarah E. Golding, Konstantin Akopiants, Frank J. Rauscher, Lawrence F. Povirk, Kristoffer Valerie
Journal: Cancer Research (2010)

Abstract The effect of ATM signaling on nonhomologous end joining (NHEJ) was investigated using a novel, chromosomally-integrated, viral vector that allows for inducing tandem I-SceI-mediated DNA double strand breaks (DSBs). The DSBs can then be analyzed for NHEJ repair events by fluorescence- and PCR-based methods. Using highly specific kinase inhibitors and this repair system, we show that inhibiting ATM reduces NHEJ by 80% in human U87 glioma cells. PCR products that span the repaired DSBs were analyzed by cleavage with a restriction enzyme that exclusively cuts the DNA repaired by high-fidelity repair. This analysis showed that the extent of high-fidelity repair was reduced by 40% when the ATM kinase was inhibited. KAP1 is a DNA damage-induced phosphorylation target of ATM that is linked to the modulation of chromatin structure. The ATM kinase inhibitor used in our studies blocks radiation-induced phosphorylation of KAP1 on serine 823/4. Knocking down KAP1 via shRNA had no effect on homologous recombination repair, but reduced NHEJ by 80%. Simultaneous treatment of cells with the ATM inhibitor and trichostatin A, a histone deacetylase inhibitor that promotes chromatin decondensation, abrogated the effect of the ATM inhibitor. These data are consistent with the hypothesis that ATM regulates DNA accessibility in chromatin. Together, these results suggest that ATM is critical for NHEJ of I-SceI DSBs and for high-fidelity repair of breaks within transcriptionally-active chromatin. The requirement for ATM in this system is likely a consequence of its signaling to chromatin modulating proteins that dynamically act on chromatin architecture surrounding DSBs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3923.
Case 32-1994
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, David Weinberg, Eugene J. Mark
Journal: New England Journal of Medicine (1994)

Presentation of CaseA 61-year-old man was admitted to the Neuromuscular Clinic because of muscular weakness.The patient had been well and athletic until nine months earlier, when he experienced severe fatigue, promptly went to bed, and slept for most of the next 25 hours. Thereafter he experienced increasing weakness in the early morning that diminished during the day. He found it difficult to open screw-capped jars and was even more disabled by leg weakness on climbing stairs and getting out of automobiles. Early in the course of the illness he had muscle cramps in the legs and less frequently . . .
Ophthalmologist who tried to deflect blame onto others is struck off
Authors: C. Dyer
Journal: BMJ (2013)

A locum ophthalmologist who attempted to blame other doctors for her own inappropriate prescribing has been struck off the UK’s medical register.

Bhavdip Gill was in her first week as a locum staff grade doctor in ophthalmology for Maidstone and Tunbridge Wells NHS Trust in summer 2009 when she saw “patient A,” a woman in her late 40s who came to the accident and emergency department with a severely inflamed eye.

The Medical Practitioners Tribunal Service found that Gill did not take a proper history, failed to record the woman’s diabetes or to consider an infective cause, and prescribed steroids without obtaining informed …
FRI0151 Steroids and leflunomide, not biologics, are the major risk factors for infection following total joint arthroplasty:
Authors: R. Somayaji, C. Barnabe, L. Martin
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rheumatoid Arthritis (RA) patients are at risk for infectious complications following orthopaedic procedures due to underlying comorbidities and RA treatment. The effect of biologic therapies on the risk for infection is still controversial, with conflicting evidence from multiple investigators (1). <h3>Objectives</h3> To determine whether biologic therapies increase the risk of post-operative infection (surgical site or any site) in RA or adult juvenile idiopathic arthritis (JIA) patients undergoing hip or knee total joint arthroplasty (TJA). <h3>Methods</h3> Administrative data from the Calgary Zone of Alberta Health Services identified all RA or adult JIA patients who underwent a hip or knee TJA between January 1/2000 and December 31/2010. Clinical data, surgical details, post-operative infections and post-operative course (minimum 1 year follow-up) was extracted for each patient from the hospital chart. <h3>Results</h3> A total of 236 patients (71% female, mean age 62 years, median BMI 27.7) underwent 347 orthopedic procedures. Comorbidities included hypertension (44%), diabetes (10%), coronary artery disease (15%), smoking (13%) and obesity (38%). Almost all (98%) of patients received pre-operative antibiotics. Surgical site infections occurred in 7 procedures, and other site infections (urinary tract, respiratory, abdominal) in 4 procedures. The relative risk of a post-operative infection was not increased for patients on biologic therapies relative to those on DMARDs alone. Patients on leflunomide or on steroids (dose &gt;15 mg/day) had the highest risk for post-operative infection (Table 1). Underlying comorbidities did not affect the risk of infection (Table 1). <h3>Conclusions</h3> Biologic therapy and underlying comorbidities do not confer an increased risk of post-operative infection in RA patients undergoing hip or knee TJA. Moderate to high dose steroids and leflunomide therapy do significantly increase the risk of infection. <h3>References</h3> Goh L, Jewell T, Laversuch C, Samanta A. Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. Rheumatol Int. 2012 Jan;32(1):5-13. <h3>Disclosure of Interest</h3> None Declared
FRI0411 Response and drug survival of sulfasalazine in an observational study (nor-dmard) of dmard-naïve patients with axial spondyloarthritis (SPA)
Authors: K. M. Fagerli, D. van der Heijde, M. S. Heiberg, A. Wierød, E. Rødevand, K. Mikkelsen, S. Kalstad, T. K. Kvien, E. Lie
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Current recommendations for the treatment of ankylosing spondylitis (AS) states that sulfasalazine (SSZ) may be used for patients who have peripheral disease as there is some evidence of efficacy (1). However, SSZ is not recommended for patients with only axial disease, as there was no proof of efficacy in this group (1). <h3>Objectives</h3> Investigate the response and drug survival of SSZ in patients with axial SpA, and especially compare outcomes in patients with and without swollen joints. <h3>Methods</h3> Data is from NOR-DMARD, a Norwegian, multi-centre longitudinal observational study of DMARD treatment in inflammatory joints diseases. Patients had a clinical diagnosis of axial SpA (ICD-10: M45, M46.1, M46.8 and M46.9) and started SSZ as their first DMARD were included in the current analyses. Response was assessed by patient global assessment, physician global assessment, MHAQ, SF-6D, CRP, number of swollen joints, and ASDAS, BASDAI and ASAS responses. As BASDAI was only included in the data collection in 2006, ASDAS, BASDAI and ASAS responses were not available for all patients. Groups were compared using independent t-test, chi-square, Fisher exact test and Mann-Whitney U-test as appropriate. <h3>Results</h3> We included 181 DMARD-naïve SpA-patients who were starting treatment with SSZ. Baseline characteristics were (mean (SD) unless stated otherwise): Age 40.4 (11.9) yrs, 54.1% males, 83.8% HLA-B27 positive, disease duration median (IQR) 2.6 (0.1-11.1) yrs, 52.2% with swollen joints, ASDAS 3.1 (0.9), BASDAI 5.2(2.0), patient global 53.4 (20.8). Patients with swollen joints at baseline were somewhat older and had higher baseline CRP and ASDAS. 3-month responses were available for 139 patients, and are shown in the table. Analyses corrected for baseline differences yielded similar results. Three-year drug survival was statistically significantly better in patients with swollen joints (0.10 vs. 0.22 (p=0.03)). <h3>Conclusions</h3> Overall, responses to SSZ were modest in this population of DMARD-naïve axial SpA-patients. There was a trend towards a slightly better 3-month response and significantly better 3-year drug survival in patients with peripheral joint swelling, supporting the recommendation of SSZ in this patient group. <h3>References</h3> Braun J <i>et al.</i> Ann Rheum Dis 2011;70:896–904. <h3>Disclosure of Interest</h3> None Declared
SELECTIVE LATE INA INHIBITION BY GS967 EXERTS POTENT SUPPRESSION OF CATECHOLAMINE-INDUCED VENTRICULAR TACHYCARDIA
Authors: Afonso Alves Bento, Danilo Bacic, Juliana Saran Carneiro, Bruce Nearing, Sridharan Rajamani, Luiz Belardinelli, Richard Verrier
Journal: Journal of the American College of Cardiology (2015)
Abstract P1-14-15: Recent experience of neoadjuvant chemotherapy according to breast cancer subtype: experience from a large United Kindgom teaching hospital
Authors: T Rattay, M Kaushik, S Ahmed, S Shokuhi
Journal: Cancer Research (2012)

Abstract INTRODUCTION: The most recent United Kingdom (NICE, 2009) guidelines recommend neoadjuvant chemotherapy as the most appropriate initial treatment for locally advanced breast cancer followed by mastectomy. Neoadjuvant chemotherapy should also be offered to patients with early breast cancer who are considering breast conserving surgery that is not advisable at presentation. However, the evidence base is still gathering. This study reviews the recent experience of neoadjuvant chemotherapy in a large United Kingdom breast unit according to breast cancer subtype. METHODS: Retrospective chart review of patients who received neoadjuvant chemotherapy for breast cancer at University Hospitals of Leicester between January 2008 and March 2011. Patients were identified from the unit database. Breast cancers were typed according to immunehistochemical marker profile: luminal A (ER or PR positive, HER2 negative), luminal B (ER or PR positive, HER2 positive), triple negative (ER and PR negative, HER2 negative), and HER2 positive (ER and PR negative, HER2 positive). RESULTS: Of 2,489 new patients with breast cancer seen during the study period, 153 patients received neoadjuvant chemotherapy. 20 patients had lobular-type cancers, and the remaining 133 patients had ductal- or mixed-type histology. 101 patients had locally advanced disease and 52 patients presented as early breast cancer. 24 of all patients (15 %) achieved complete pathological response. 18 patients (12 %) never proceeded to surgery, eight of whom died during the study period. In total to date, 23 patients (15 %) have died including one death due to complications from chemotherapy. Of 120 patients initially scheduled for mastectomy, the tumor was downsized in 26 patients (22 %) so that they were able to undergo breast conserving surgery (BCS), with margins involved in six patients. The outcome of neoadjuvant chemotherapy according to breast cancer subtype is presented (Tables 1 and 2). CONCLUSIONS: In our experience, patients receive neoadjuvant chemotherapy for breast cancer for a variety of indications. Compared to our standard population of breast cancer patients, early mortality remains relatively high, particlularly in the hormone receptor negative subtypes. BCS conversion rates were similar across breast cancer subtypes, but BCS was less likely to be successful in the Luminal A group. Luminal A cancers were also significantly less likely to achieve pCR after neoadjuvant chemotherapy. Breast cancer subtype should be taken into account when scheduling patients for neoadjuvant chemotherapy. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-15.
Outcome in Patients with Asymptomatic Neck Bruits
Authors: Brian R. Chambers, John W. Norris
Journal: New England Journal of Medicine (1986)

Five hundred asymptomatic patients with cervical bruits were followed prospectively by clinical and Doppler examination for up to four years (mean, 23.2 months) to identify the variables predicting outcome. Thirty-six patients had strokes or transient ischemic attacks, 51 had cardiac ischemic events, and 45 died. At one year the incidence of cerebral ischemic events (transient ischemic attacks and strokes) was 6 percent, that of cardiac ischemic events was 7 percent, and that of death was 4 percent. The overall incidence of stroke at one year was 1.7 percent (1 percent in patients without previous transient ischemic attacks), but the incidence was 5.5 percent in patients with severe carotid-artery stenosis (>75 percent). Cerebral ischemic events were most frequent in patients with severe carotid-artery stenosis (P<0.0001), progressing carotid-artery stenosis (P<0.0005), or heart disease (P<0.0005) and in men (P<0.025). The degree of carotid-artery stenosis on initial presentation was a powerful predictor of neurologic sequelae. Patients with asymptomatic cervical bruits have a higher risk of a cardiac ischemic event than of a stroke. Although the risk of cerebral ischemic events is highest in patients with severe carotid-artery stenosis, in most instances even these patients do not have strokes without some warning. (N Engl J Med 1986; 315:860–5.)
Endoscopic intracavitary vacuum sponge therapy of anastomotic leakage in the proximal colon after right-sided colectomy
Authors: G. Loske, T. Schorsch, C. Müller
Journal: Endoscopy (2010)

Anastomotic leakage is the most severe complication following colon resection. Surgical treatment includes resection of the anastomosis or fecal diversion via ileostomy or colostomy. Since 2006 we have adopted the principle of intracavitary vacuum therapy to treat patients with various intestinal defects [1] [2] [3]. This case report represents the first description of successful endoscopic treatment of anastomotic leakage in the proximal colon after right-sided colectomy using intracavitary vacuum sponge drainage.